NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the […]
NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment
New York, December 19, 2023 – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens […]